Bulky primary tibia mantle cell lymphoma achieved complete remission with CHOP and DHAP plus rituximab: A case report
- Authors:
- Published online on: August 29, 2018 https://doi.org/10.3892/ol.2018.9370
- Pages: 6116-6120
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Mantle cell lymphoma (MCL) is a subtype of B‑cell non‑Hodgkin lymphoma. Heterogeneous and extensive lymphadenopathy is the most common clinical manifestation. Although skeletal involvement is not uncommon in other types of non‑Hodgkin lymphoma, primary bone MCL is rare. The present study reported a case of primary tibia MCL in a 50‑year‑old male presenting with left tibia pain and a rapidly growing lump. Computed tomography and magnetic resonance imaging scans revealed a progressive lesion in the cortical bone and surrounding soft tissue mass. A positron emission computed tomography scan demonstrated increased glucose metabolism in the middle tibia without involvement of regional lymph nodes. An aspiration biopsy was performed, and pathological examination revealed small‑medium sized cells strongly positive for cluster of differentiation (CD)5, CD20 and cyclin D1. Fluorescent in situ hybridization analysis confirmed the presence of immunoglobulin heavy chain/cyclin D1 gene fusion formed by t(11;14) translocation. As a result, primary bone MCL was diagnosed and rituximab‑containing chemotherapy was administered. Following complete remission, autologous hemopoietic stem cell transplantation and rituximab maintenance therapy were performed. During the 2‑year follow‑up period, the patient remained in a good condition without signs of relapse.
